Skip to main content

JOHNSON & JOHNSON

corporate_fare Company Profile

JOHNSON & JOHNSON

JNJ·NYSE·Life Sciences·CIK 0000200406

Johnson & Johnson is a global healthcare company with approximately 138,200 employees worldwide. The company focuses on the research, development, manufacturing, and sale of a wide range of products primarily related to human health and well-being. Incorporated in New Jersey in 1887, Johnson & Johnson operates through its subsidiaries in virtually all countries globally. The company is structured into two main business segments: Innovative Medicine and MedTech. The Innovative Medicine segment concentrates on several therapeutic areas. These include Oncology, addressing conditions such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer. In Immunology, the focus is on rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis. Neuroscience covers mood disorders, neurodegenerative disorders, and schizophrenia. The segment also addresses Pulmonary Hypertension, specifically Pulmonary Arterial Hypertension, and Infectious Diseases like HIV/AIDS. Additionally, it covers Cardiovascular and Metabolism, including thrombosis, diabetes, and macular degeneration. Products within the Innovative Medicine segment are distributed for prescription use directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals.

JOHNSON & JOHNSON (NYSE:JNJ) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 54 items for JNJ at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • J&J's Nipocalimab-aahu Phase 3 Study Shows Sustained Improvements for Autoantibody Disease
  • Judge Rejects Bayer's Bid to Block J&J's Multibillion-Dollar Prostate Cancer Drug Claims
  • J&J Talc Bankruptcy Plan Voided by Court, Reopening Lawsuits; Q1 Revenue Hits $24B, Guidance Raised
  • Johnson & Johnson Reports Strong Q1, Raises 2026 Guidance, and Increases Dividend for 64th Consecutive Year
  • J&J's Innovative Medicine Sales Growth Fueled by Darzalex, Carvykti, Erleada, Rybrevant, Tremfya, and Spravato

Financial Snapshot

Fiscal year ended December 28, 2025
Revenue
$94.19B
Net Income
$26.8B
Diluted EPS
$11.03
Op. Cash Flow
$24.53B
Free Cash Flow
$19.7B
Gross Profit
$63.94B
Cash & Equivalents
$19.71B
Total Debt
$41.44B
Debt / Equity
0.51×
Net Margin
28.5%
Shares Outstanding
2.41B sh
Source: 10-K · filed 2026-02-11 · accession 0000200406-26-000016
$266.2 +0.62% today
52-week range · as of 2026-08-13 $172.69 – $274.9
Market cap
$640.02B
Volume
4.7M (0.7× avg)
3-mo avg 6.4M
Live data · 2026-09-13 20:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed JNJ - Filings & News (Page 3)

JNJ
Apr 22, 2026, 10:40 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $226.29
Real-time Price: $266.20 info
Change: +$39.91 (+18%) info
Market Cap: $640.021B info
JNJ
Apr 17, 2026, 6:47 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $233.50
Real-time Price: $266.20 info
Change: +$32.70 (+14%) info
Market Cap: $640.021B info
JNJ
Apr 14, 2026, 4:07 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $240.10
Real-time Price: $266.20 info
Change: +$26.10 (+11%) info
Market Cap: $640.021B info
JNJ
Apr 14, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $236.36
Real-time Price: $266.20 info
Change: +$29.84 (+13%) info
Market Cap: $640.021B info
JNJ
Apr 14, 2026, 6:20 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $236.42
Real-time Price: $266.20 info
Change: +$29.78 (+13%) info
Market Cap: $640.021B info
JNJ
Apr 13, 2026, 12:44 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $235.52
Real-time Price: $266.20 info
Change: +$30.68 (+13%) info
Market Cap: $640.021B info
JNJ
Mar 30, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $242.33
Real-time Price: $266.20 info
Change: +$23.87 (+10%) info
Market Cap: $640.021B info
JNJ
Mar 28, 2026, 10:03 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $240.66
Real-time Price: $266.20 info
Change: +$25.54 (+11%) info
Market Cap: $640.021B info
JNJ
Mar 27, 2026, 3:04 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $241.13
Real-time Price: $266.20 info
Change: +$25.07 (+10%) info
Market Cap: $640.021B info
JNJ
Mar 09, 2026, 1:07 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $242.70
Real-time Price: $266.20 info
Change: +$23.50 (+10%) info
Market Cap: $640.021B info
JNJ
Mar 06, 2026, 3:03 PM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $239.28
Real-time Price: $266.20 info
Change: +$26.92 (+11%) info
Market Cap: $640.021B info
JNJ
Mar 03, 2026, 8:11 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $246.05
Real-time Price: $266.20 info
Change: +$20.15 (+8%) info
Market Cap: $640.021B info
JNJ
Feb 11, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $241.13
Real-time Price: $266.20 info
Change: +$25.07 (+10%) info
Market Cap: $640.021B info
JNJ
Jan 21, 2026, 7:46 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $212.95
Real-time Price: $266.20 info
Change: +$53.25 (+25%) info
Market Cap: $640.021B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets